Insider Selling: Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Sells 17,101 Shares of Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Richard K. Prins sold 17,101 shares of the firm’s stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $43.07, for a total value of $736,540.07. Following the completion of the transaction, the director now owns 33,971 shares of the company’s stock, valued at approximately $1,463,130.97. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Amphastar Pharmaceuticals Price Performance

Shares of NASDAQ:AMPH opened at $45.32 on Friday. The company’s fifty day moving average price is $40.43 and its 200-day moving average price is $43.70. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.18 and a quick ratio of 1.72. The firm has a market capitalization of $2.22 billion, a price-to-earnings ratio of 15.68, a PEG ratio of 0.75 and a beta of 0.79. Amphastar Pharmaceuticals, Inc. has a one year low of $36.56 and a one year high of $65.92.

Wall Street Analyst Weigh In

AMPH has been the subject of a number of analyst reports. Piper Sandler cut their price objective on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating for the company in a research report on Thursday, August 8th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Thursday, August 8th. Finally, StockNews.com downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, August 9th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, Amphastar Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $63.00.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in AMPH. Quadrant Capital Group LLC lifted its stake in Amphastar Pharmaceuticals by 27.8% during the fourth quarter. Quadrant Capital Group LLC now owns 1,026 shares of the company’s stock worth $63,000 after purchasing an additional 223 shares during the last quarter. Bridge City Capital LLC lifted its position in Amphastar Pharmaceuticals by 0.8% in the 1st quarter. Bridge City Capital LLC now owns 34,773 shares of the company’s stock worth $1,527,000 after buying an additional 275 shares during the last quarter. Crossmark Global Holdings Inc. boosted its stake in Amphastar Pharmaceuticals by 2.5% in the second quarter. Crossmark Global Holdings Inc. now owns 11,300 shares of the company’s stock worth $452,000 after buying an additional 275 shares in the last quarter. Blue Trust Inc. grew its position in Amphastar Pharmaceuticals by 23.9% during the second quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock valued at $70,000 after acquiring an additional 309 shares during the last quarter. Finally, Nations Financial Group Inc. IA ADV raised its stake in shares of Amphastar Pharmaceuticals by 2.7% during the first quarter. Nations Financial Group Inc. IA ADV now owns 14,923 shares of the company’s stock worth $655,000 after acquiring an additional 399 shares in the last quarter. Institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.